The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Selecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoring
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, comments on the current approach to determining which patients with acute myeloid leukemia (AML) should undergo transplantation. Dr Cluzeau notes that while patients with adverse risk typically receive transplants, the decision for those with intermediate risk is less clear, with ongoing research investigating the role of measurable residual disease (MRD) status in guiding treatment choices. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so today there is a question to know which patient we need to transplant in high-risk myeloma leukemia. So as you know, recently there is an update of ELN classification. So the ELN classification determines and stratifies the patient into favorable, intermediate, and adverse risk. So usually, you do not transplant the patient with favorable risk, with the exception of MRD. So if there is not a good clearance of MRD, this patient could have a transplant in the first line...
Yes, so today there is a question to know which patient we need to transplant in high-risk myeloma leukemia. So as you know, recently there is an update of ELN classification. So the ELN classification determines and stratifies the patient into favorable, intermediate, and adverse risk. So usually, you do not transplant the patient with favorable risk, with the exception of MRD. So if there is not a good clearance of MRD, this patient could have a transplant in the first line. And there is a question for the intermediate, and we transplant all the patients with adverse risk. So the question for the intermediate is because today we have new tools, and the new tool is the MRD. So we could have access to MRD, flow MRD, NGS MRD, PCR MRD depending on the characteristic of the disease and the question is still open, so today the ELN recommends to transplant all the patients, all intermediate ones and all adverse patients, but there is some question and today there is a randomized clinical trial in intermediate-risk patients with negative minimal residual disease and we randomize the patient between allogeneic transplant and chemotherapy consolidation alone, so for today, we need to continue to transplant, but maybe in the future, using MRD, we can decide not to transplant maybe a small subset of patients. So the best factor to decide if you need to transplant or not the patient is, of course, the disease characteristics, so the molecular risk as we discussed just before, but there is also the age, the characteristic of the donor, which transplant we can propose to the patient, the age is not a limit, but this is a parameter we need to consider to define if the patient could have a transplant or not, and maybe in the future, the minimal residual disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
